Rebiotix

OverviewSuggest Edit

Rebiotix Inc is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating gastrointestinal (GI) diseases by harnessing the power of the human microbiome. The company is on the forefront of an exciting potential medical breakthrough, Microbiota Restoration Therapy (MRT). MRT is the Rebiotix Drug Platform for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease. Rebiotix looks to deliver on the promise of restoring the gut microbiota via a standardized and stabilized drug that has been developed and tested under the auspices of a regulatory authority.
TypePrivate
Founded2011
HQSaint Paul, MN, US
Websiterebiotix.com
Overall CultureA+

Latest Updates

Employees (est.) (Oct 2021)81(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Rebiotix

Lee Jones

Lee Jones

Founder, President & CEO
Greg Fluet

Greg Fluet

Chief Operating Officer
Nancy Timm

Nancy Timm

VP, Finance and Operations
Show more

Rebiotix Office Locations

Rebiotix has an office in Saint Paul
Saint Paul, MN, US (HQ)
2660 Patton Rd
Show all (1)

Rebiotix Financials and Metrics

Summary Metrics

Founding Date

2011

Rebiotix total Funding

$27.8 m

Rebiotix latest funding size

$25 m

Time since last funding

7 years ago
Rebiotix's latest funding round in August 2014 was reported to be $25 m. In total, Rebiotix has raised $27.8 m
Show all financial metrics

Rebiotix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Rebiotix Online and Social Media Presence

Embed Graph

Rebiotix Company Culture

  • Overall Culture

    A+

    91/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A

    89/100

Learn more on Comparably

Rebiotix News and Updates

Microbiome Landscape Clinical Trial Analytics Report 2021: 2020 Saw 3 Key Clinical Trial Successes that have Spurred the Industry, Namely that of Seres, Rebiotix, and Finch

DUBLIN, Aug. 24, 2021 /PRNewswire/ -- The "2021 Clinical Trial Analytics of the Microbiome Landscape" report has been added to ResearchAndMarkets.com's offering. The number of ongoing clinical trials with a focus on the microbiome has risen substantially from 2015-2019 to 190 trials, with...

Hepatic Encephalopathy: Market competition to grow in forecast period due to foray of more players

WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Hepatic Encephalopathy - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday

Rebiotix Blogs

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI…

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of t…

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)

Ken Blount PhD, Courtney Jones BS, Sharina Carter PhD, Elena Deych MS, Bill Shannon PhD MBA Background Because Clostridium difficile infections (CDI) are strongly associated with dysbiosis, or disruption of a healthy microbiome, there are several clinical development programs in progress to develop …

Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660

The post Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660 appeared first on Rebiotix.

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

The post Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660 appeared first on Rebiotix.

Rebiotix Frequently Asked Questions

  • When was Rebiotix founded?

    Rebiotix was founded in 2011.

  • Who are Rebiotix key executives?

    Rebiotix's key executives are Lee Jones, Greg Fluet and Nancy Timm.

  • How many employees does Rebiotix have?

    Rebiotix has 81 employees.

  • Who are Rebiotix competitors?

    Competitors of Rebiotix include Adaptimmune, Harbour Antibodies and GrayBug.

  • Where is Rebiotix headquarters?

    Rebiotix headquarters is located at 2660 Patton Rd, Saint Paul.

  • Where are Rebiotix offices?

    Rebiotix has an office in Saint Paul.

  • How many offices does Rebiotix have?

    Rebiotix has 1 office.